- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00441818
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma
A Phase I/II, Non-Randomized,Multiple-Dose,Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TNX-650 in Patients With Refractory Hodgkin's Lymphoma
Study Overview
Detailed Description
Hodgkin's lymphoma (HL) is a lymphoid malignancy that accounts for approximately 7,000 to 8,000 new cancer cases per year in the United Sates. It occurs with a bimodal age-incidence distribution peaking in the 15- to 30-year old and 50- to 60-year old age groups. The pathological hallmark of the disease is the presence of malignant Reed Sternberg (RS) cells. Reed-Sternberg cells are interspersed among a heterogeneous population of non-malignant reactive cells, including T cells, eosinophils, neutrophils, B lymphocytes, plasma cells, histiocytes, fibroblasts, and stromal cells.
While more than 80% of patients will respond to initial radiotherapy or combination chemoradiotherapy, some patients will experience early relapse after initial therapy or be refractory to first-line therapy. These patients may be treated with second-line therapy, which may include autologous bone marrow transplantation (BMT). Patients with HL who relapse after first- and second-line therapy, or who are refractory to therapy, with or without autologous BMT, have a poor prognosis. The long-term event-free survival rate in this patient group is less than 10%; median survival is 16 months. At present, these patients have no treatment options other than investigational therapies.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Fatai Osinowo, MD
- Phone Number: 713-578-4332
- Email: fosinowo@tanox.com
Study Contact Backup
- Name: Tad Iwan
- Phone Number: 713-578-4181
- Email: tiwan@tanox.com
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Not yet recruiting
- Memorial Sloan-Kettering Cancer Center
-
Contact:
- Bri-Anne Wilson
- Phone Number: 646-227-2191
- Email: wilsonb1@mskcc.org
-
Contact:
- Sarah Alandra Weaver
- Phone Number: 646-227-2133
- Email: weavers@mskcc.org
-
Principal Investigator:
- Craig Moskowitz, MD
-
-
Texas
-
Houston, Texas, United States, 77030-4009
- Recruiting
- MD Anderson Cancer Center - Dept. of Lymphoma and Myeloma
-
Contact:
- Amanda Wedgewood, RN
- Phone Number: 713-792-9455
- Email: awedgewood@mdanderson.org
-
Principal Investigator:
- Anas Younes, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological diagnosis of relapsed or refractory classical HL
- Age >18 years
- Received and failed potentially curative chemotherapeutic regimens (e.g., ABVD, Stanford V, or BEACOPP)
- Relapsed following autologous bone marrow transplantation (BMT), or are ineligible, or refused BMT
- Completed radiotherapy, chemotherapy, and/or treatment with other investigational agents at least 3 weeks prior to study entry
- Completed autologous BMT (if received) at least 3 months prior to study entry; completed allogeneic BMT (if received); at least 6 months prior to study entry
- Eastern Cooperative Oncology Group (ECOG) status of <2
- Life expectancy of >3 months
Laboratory data:
- Platelet count >50,000/mm3
- Hemoglobin >9.0 g/dL (may be maintained by transfusion)
- Absolute neutrophil count >1000/mm3
- ALT/AST <2.5 times the upper limit of normal (ULN)
- Total bilirubin <1.5 times ULN
- Creatinine <1.5 mg/dL
- Female subjects of childbearing potential must have a negative serum pregnancy test at screening; subjects must agree to use a medically appropriate form of birth control from screening until 6 months after the last dose of study medication
- Ability to provide written informed consent
Exclusion Criteria:
- Any significant diseases (other than HL) or clinically significant findings, including psychiatric and behavioral problems, medical history and/or physical examination findings that would preclude the subject from participating in the study
- History or clinical evidence of cnetral nervous system (CNS) HL
- Received allogeneic BMT
- Received growth factor support or transfusions to achieve hematology entry criteria (platelets, hemoglobin, absolute neutrophil count)
- Major surgery within 4 weeks prior to study entry
- Known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation
- Known history of another primary malignancy that has not been in remission for at least 5 years. Non-melanoma skin cancer and cervical carcinoma in situ or squamous intraepithelial lesions (e.g., cervical intraepithelial neoplasia [CIN] or prostatic intraepithelial/intraductal neoplasia [PIN]) are allowed.
- Any active viral, bacterial, or systemic fungal infection within 4 weeks prior study entry
- Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV)
- Histry of significant chronic or recurrent infections requiring treatment
- Receiving systemic steroids exceeding 10 mg prednisone or equivalent, or unstable on steroid medication, during the 3 weeks immediately preceding enrollment
- Pregnant or breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To determine the safety and tolerability of TNX-650 for Injection when administered to patients with refractory Hodgkin's Lymphoma (HL)
|
To determine the maximum tolerated dose (MTD) of TNX-650 for Injection
|
To determine the systemic exposure to TNX-650 for Injection in patients with refractory HL
|
To determine phosphorylated STAT-6 and IL-13Rα1 levels in tumor samples, and serum IL 13 levels, which may be useful as early prognostic indicators of efficacy in later clinical studies
|
To determine the preliminary efficacy of TNX-650 for Injection at the maximum tolerated dose (MTD) or pharmacologically active dose, if MTD is not reached, based on tumor assessments using computed tomography (CT) or magnetic resonance imaging (MRI), and
|
Secondary Outcome Measures
Outcome Measure |
---|
To determine phosphorylated STAT-6 and IL-13Rα1 levels in tumor samples, and serum IL 13 levels, which may be useful as early prognostic indicators of efficacy in later clinical studies
|
To determine the safety profile of TNX-650 for Injection at the MTD
|
To determine the preliminary efficacy of TNX-650 for Injection at the MTD, based on tumor assessments using CT or MRI, and FDG-PET
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anas Younes, MD, M.D. Anderson Cancer Center
- Principal Investigator: Craig Moskowitz, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TNX-650.101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin's Lymphoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
-
Western Regional Medical CenterWithdrawnLymphoma | Hodgkin's Lymphoma | Non-hodgkin's LymphomaUnited States
-
Spectrum Pharmaceuticals, IncCTI BioPharmaTerminatedLymphoma, Follicular | Follicular LymphomaUnited States
Clinical Trials on TNX-650
-
Tonix Pharmaceuticals, Inc.Premier Research Group plcActive, not recruitingDetection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2United States
-
Tonix Pharmaceuticals, Inc.Completed
-
Tonix Pharmaceuticals, Inc.CompletedTension-Type HeadacheUnited States
-
Volastra Therapeutics, Inc.AmgenCompletedAdvanced Solid TumorsUnited States, Canada, Italy, Australia, Japan, Belgium, Spain
-
Tenax Therapeutics, Inc.Medpace, Inc.RecruitingPulmonary HypertensionUnited States
-
Mitsubishi Tanabe Pharma CorporationCompletedBehcet Syndrome | Behcet's Disease | Neuro-Behcet's DiseaseJapan
-
Tonix Pharmaceuticals, Inc.Completed
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Tonix Pharmaceuticals, Inc.Completed
-
Tonix Pharmaceuticals, Inc.CompletedCOVID-19 | Long COVID | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection | Long Haul COVIDUnited States